The global digital diabetes management market size was valued at USD 11.8 billion in 2022 and is expected to expand at a compound annual growth rate (CAGR) of 8.3% from 2023 to 2030. The market’s robust growth is majorly attributed to the growing prevalence of diabetes, coupled with technological advancements and innovations. As per the International Diabetes Federation, around 537 million adults were living with diabetes in 2021, with the number expected to reach 783 million by 2045. As digital technology is continuously advancing, the market is expected to witness a wide range of innovations within the diabetes space, which has the potential to change the way we manage the disease. The number of smartphone apps available for diabetes management has increased sharply in recent years, and over a hundred apps are available on web-based app stores that can help patients monitor their blood glucose levels.
Rapidly changing lifestyle patterns, such as smoking and increasing consumption of alcohol, are expected to contribute to the increasing incidence of diabetes worldwide. Moreover, obesity is another major factor in the fast-growing number of diabetes patients. The market for diet and weight management apps is showing great potential with the increasing obese population, coupled with the growing awareness regarding these services among patients.
Diabetes is a clinical condition where the inability of the pancreas to produce insulin causes an increase in glucose levels in the body. Diabetic patients face many daily challenges, such as not knowing what to eat, understanding medical advice, and the impact of food and activity on sugar. The anytime and everywhere nature of digital technologies enables patients to address their health concerns by communicating with the medical staff and exchanging data. Connecting patients and their care teams has developed a digital ecosystem of data-driven solutions to improve diabetes treatment.
The COVID-19 pandemic positively impacted the digital diabetes management devices market. Managing blood glucose levels became critical for patients admitted to hospitals with severe lung infections. Medications used to treat the disease led to a significant change in patient blood glucose levels. Moreover, the Centers for Disease Control and Prevention highlighted that people living with diabetes and diagnosed with COVID-19 were at high risk of being admitted to critical care. Thus, the need for using diabetes management devices significantly increased.
The continuous blood glucose monitoring system segment held the largest revenue share of over 40.6% in 2022, owing to its advanced features such as compatibility with smart devices that serve as display devices. Moreover, it can be set to send custom alerts to patients when certain glucose thresholds are reached. Based on products, the market has been segmented into smart insulin pens, continuous blood glucose monitoring systems, smart glucose meters, smart insulin pumps, and apps. Diabetes management apps are divided into digital diabetes management apps and weight & diet management apps.
The smart insulin pens segment is expected to expand at the fastest growth rate of 11.4% during the forecast period. The segment's high growth is majorly attributed to the increasing number of product launches and the advent of artificial intelligence. Many players focus on developing innovative smart insulin pens, expanding their presence, and increasing product offerings, thus driving the market. For instance, in March 2022, Novo Nordisk launched smart insulin pens in the UK. Patients receiving care for diabetes through the NHS now have access to the first-ever monitoring and recording technology.
Based on end-use, the digital diabetes management market is segmented into hospitals, home settings, and diagnostic centers. Hospitals can use digital platforms or mobile apps that provide diabetes education, self-management tools, and support, as well as offer them to patients. With these technologies, patients may better understand their condition, monitor their blood sugar levels, take control of their medication, and get advice from medical specialists.
Patients can use digital devices such as glucometers and insulin pumps at their convenience, which has increased the demand for such devices. Larger diagnostic centers may have specific sections or programs to manage diabetes digitally. They can help patients by creating individualized care plans, prescribing appropriate devices, and offering consultations.
The wearable devices segment held the largest revenue share of 56.9% in 2022, and the segment is expected to expand at the fastest CAGR of 8.4% over the forecast period. The segment's growth is majorly attributed to technological advancements such as the advent of artificial intelligence, the launch of new products such as closed-loop pump systems and smart insulin patches, and the growing adoption of self-insulin delivery devices in diabetes management. The market is segmented based on type into wearable devices and handheld devices.
The handheld devices segment also held a considerable revenue share in 2022, and its growth is primarily attributed to technological advancements and new product launches. Handheld diabetes devices can measure and record blood glucose levels, calculate how much insulin has to be administered, receive patient data via a user interface, archive patient data, and perform other activities. In June 2018, Insulet received FDA approval for its handheld ‘Omnipod DASH’ system. The device is a touchscreen personal diabetes manager with Wi-Fi connectivity that allows the software to be remotely updated.
North America led the market in 2022 with a revenue share of over 38.0%, aided by the availability of advanced technologies and the recent approval of many digital blood glucose patient monitoring devices in the region. For instance, in January 2022, Insulet Corporation announced that it had received clearance from the U.S. FDA for its Omnipod 5 Automated Insulin Delivery System. It is a unique system that integrates with Dexcom G6 Continuous Glucose Monitoring (CGM). It facilitates remote patient monitoring and data transfer through the Omnipod 5 mobile app with its integrated SmartBolus Calculator. The increasing geriatric population and the growing burden of diabetes due to lifestyle changes are expected to boost regional market growth.
On the other hand, the Asia Pacific region is expected to witness the fastest CAGR of 9.8% over the forecast period, owing to new product launches, a large diabetic population base, and increasing government initiatives in the region. For instance, in January 2022, the Australian Centre for Accelerating Diabetes Innovations (ACADI) at the University of Melbourne announced that the federal government would grant the center USD 10 million over a 4-year period. The ACADI will be a new virtual research center that will connect research centers around Australia and help important industry partners and organizations develop new therapies, technologies, and behavioral interventions to address issues related to diabetes in the country.
Major market players focus on adopting new technologies and introducing advanced products, taking advantage of important cooperation activities, and exploring acquisitions and government initiatives to offer their customers better services and strengthen their market presence. For instance, in August 2022, Abbott Laboratories announced its collaboration with WeightWatchers to launch new digital tools to emphasize the importance of weight loss and controlling blood sugar in diabetes patients. Abbott integrated its recent digital glucose monitoring technology into WeightWatchers' diabetes-specific program, as a part of this strategic partnership.
In another instance, in May 2021, Ascensia Diabetes Care launched a browser-based diabetes management and analytics platform, GlucoContro.online, that provides data-driven care for people who use any of the CONTOUR blood glucose monitoring meters. In September 2021, Ypsomed AG partnered with Dexcom, a market leader in CGM systems. This partnership was intended to make data from Dexcom G6 CGM devices available in the Ypsomed application in a smart device. Following are some of the major participants in the global digital diabetes management market:
F. Hoffmann-La Roche Ltd.
Ascensia Diabetes Care Holdings AG
B. Braun Melsungen AG
Market size value in 2023
USD 12.56 billion
Revenue forecast in 2030
USD 21.9 billion
CAGR of 8.3% from 2023 to 2030
Base year for estimation
2018 - 2021
2023 - 2030
Revenue in USD million and CAGR from 2023 to 2030
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Product, type, end-use, region
North America; Europe; Asia Pacific; Latin America; MEA
U.S.; Canada; U.K.; Germany; France; Italy; Spain; Denmark; Sweden; Norway; Japan; China; India; Australia; South Korea; Thailand; Brazil; Mexico; Argentina; South Africa; Saudi Arabia; UAE; Kuwait
Key companies profiled
Abbott; Medtronic; F. Hoffmann-La Roche Ltd.; Bayer AG; LifeScan, Inc.; Dexcom, Inc.; Sanofi; Insulet Corporation; Ascensia Diabetes Care Holdings AG; B. Braun Melsungen AG
Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope
Pricing and purchase options
Avail customized purchase options to meet your exact research needs. Explore purchase options
This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the global digital diabetes management market report based on product, type, end-use, and region:
Product Outlook (Revenue, USD Million, 2018 - 2030)
Smart Glucose Meter
Continuous Blood Glucose Monitoring System
Smart Insulin Pens
Smart Insulin Pumps
Digital Diabetes Management Apps
Weight & Diet Management Apps
Type Outlook (Revenue, USD Million, 2018 - 2030)
End Use Outlook (Revenue, USD Million, 2018 - 2030)
Regional Outlook (Revenue, USD Million, 2018 - 2030)
Middle East & Africa
b. The global digital diabetes management market size was estimated at USD 11.8 billion in 2022 and is expected to reach USD 12.56 billion in 2023.
b. The global digital diabetes management market is expected to grow at a compound annual growth rate of 8.3% from 2023 to 2030 to reach USD 21.90 billion by 2030.
b. North America dominated the digital diabetes management market with a share of 38.6% in 2022. This is attributable to the increasing penetration of smart consumer devices and innovation in AI-based services.
b. Some key players operating in the digital diabetes management market include Abbott Laboratories; Medtronic plc; F. Hoffmann-La Roche Ltd; Bayer AG; Lifescan, Inc.; Dexcom, Inc.; Sanofi; Insulet Corporation; Ascensia Diabetes Care Holdings Ag; and B Braun Melsungen AG.
b. Key factors that are driving the digital diabetes management market growth include increasing technological advancements and rising FDA approval for innovative products.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
"The quality of research they have done for us has been excellent."